Validation by Peer-Reviewed Publications

Publications

2022

Descamps L, Garcia J, Barthelemy D, Laurenceau E, Payen L, Le Roy D, Deman AL. MagPure chip: an immunomagnetic-based microfluidic device for high purification of circulating tumor cells from liquid biopsies. Lab Chip. 2022 Sep 23. doi: 10.1039/d2lc00443g. Epub ahead of print. PMID: 36148526.
Rousset X, Maillet D, Grolleau E, Barthelemy D, Calattini S, Brevet M, Balandier J, Raffin M, Geiguer F, Garcia J, Decaussin-Petrucci M, Peron J, Benzerdjeb N, Couraud S, Viallet J, Payen L. Embryonated Chicken Tumor Xenografts Derived from Circulating Tumor Cells as a Relevant Model to Study Metastatic Dissemination: A Proof of Concept. Cancers (Basel). 2022 Aug 23;14(17):4085. doi: 10.3390/cancers14174085. PMID: 36077622; PMCID: PMC9454737.

2019

Lin et. al., “Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy” October 2019, DOI: 10.1373/clinchem.2019.307140
Whole transcriptomics analyses of mimicking Circulating Tumor Cells (CTCs) by single-cell RNA sequencing (scRNAseq)
Lim et.al. 2019, “Liquid biopsy: one cell at a time.”, PubMed, 2019
Yap et. al., “Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform”, 25 September 2019, PLOS
Lim et. al., , Addressing cellular heterogeneity in tumor and circulation for refined prognostication, PNAS, 15 August 2019
Garcia et. al. Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence, J. Vis. Exp. (150), e59873, doi:10.3791/59873 (2019)
Onidani K, Shoji H, Kakizaki T, et al. “Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA”. Cancer Sci. 2019;00:1–10. h t t p s : //d o i .org/10.1111/cas.14092

2018

Marker-Free Microfluidic Enrichment Enables Full-Length mRNA Transcriptome Analysis of Single Live Circulating Tumor Cells from Six Breast Cancer subjects Single Cell Genomics 2018; Poster # 77
Kulasinghe et al., “The prognostic significance of circulating tumor cells in head and neck and non‐small‐cell lung cancer”, Cancer Medicine, Volume 7, Issue 12, 22 November 2018
Liu et. al., “Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer”, J Cancer, 2018; 9(11): 2038–2045
Live single cell mass spectrometry reveals cancer‐specific metabolic profiles of circulating tumor cells
Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance

2017

Lee YH et al., “Biomechanics approaches to studying human diseases”, April 2017
Tan CL et al., “Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer”, Oncotarget. 2017 Jul 31;8(35):59408-59416.
Teo J et al., “A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry.”, Future Sci OA. 2017 Sep 4;3(4):FSO244
Wong CL et al., “Succinct workflows for circulating tumor cells after enrichment: From systematic counting to mutational profiling”, PLOSOne, 08 May 2017

2014

Khoo BL et al., “Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells”, PLOSone, 07 July 2014
Warkiani et al., “An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells”, Analyst, Issue 13, 2014
Warkiani et al., “Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells”, Lab on a Chip, Issue 1, 2014

2013

Hou HW et.al., “Isolation and retrieval of circulating tumor cells using centrifugal forces”, Sci Report, 12 February 2013


Posters

2019

Whole transcriptomics analyses of mimicking Circulating Tumor Cells (CTCs) by single-cell RNA sequencing (scRNAseq)

2018

Marker-Free Microfluidic Enrichment Enables Full-Length mRNA Transcriptome Analysis of Single Live Circulating Tumor Cells from Six Breast Cancer subjects Single Cell Genomics 2018; Poster # 77

2017

Correlation between HER2 and ALK status in circulating tumor Cells (CTCs) and tissue of breast and lung cancer patients
Label-free Enrichment and Integrated Full-length mRNA Transcriptome Analysis of Single Circulating Tumour Cells from Blood Sample
Label-Free Enrichment and Integrated Full-Length mRNA Transcriptome Analysis of Single Live Circulating Tumor Cells from Breast Cancer Patients
Liquid Biopsy Based Monitoring of PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC Patients for Immunotherapy

2016

Abstract 11516: Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC)
Characterization of PD-L1 expression on circulating tumor cells (CTCs) isolated with a label-free inertial microfluidic system from advanced non-small cell lung cancer patients (NSCLC pts)
ClearCell FX®, a marker-independent process for enriching viable circulating tumour cells (CTCs) from melanoma patients’ blood.
Detection of PD-L1 and PD-L2 on Circulating Tumor Cells (CTCs) Using Microfluidic Based Chipcytometry
Elucidating HER2 molecular heterogeneity of circulating tumor cells among breast cancer patients
Highly Accurate Genetic Profiling of Circulating Tumor Cells using a Label-free Inertial Microfluidic Approach Coupled with Droplet PCR-based Next-Generation Sequencing
Label-free Enrichment and Integrated Full-length mRNA Transcriptome Analysis of Single Circulating Tumour Cells from Blood Sample
Molecular characterization of PD-L1 status of circulating tumor cells (CTCs) isolated with a novel label-free inertial microfluidic system from patients (pts) with advanced cancers
Next-generation sequencing of circulating tumor cells isolated from peripheral blood of patients with head and neck or gastrointestinal cancer
Real-time HER2 Status Monitoring Using Circulating Tumour Cells

2015

Genetic Profiling of Circulating Tumor Cells using a Label-free Inertial Microfluidic Approach Coupled with Downstream Next Generation Sequencing
High Purity Isolation of Circulating Tumor Cells For Next Generation Sequencing
Label free isolation of circulating tumor cells from castration-resistant prostate cancer patients discovers a novel androgen receptor transcriptional variant as a potential prognosis biomarker

2014

Fully Automated Label-Free Microfluidic System For Circulating Tumor Cell Enrichment

For Research Use Only (RUO)

** for In Vitro Diagnostic use, please contact Biolidics’s representative for further information.

ClearCell® FX Brochure
Locate Us
Contact Us